The NCI60 human tumour cell line anticancer drug screen
The NCI60 human tumour cell line anticancer drug screen
复制标题
DOI：
10.1038/nrc1951
复制
发表时间：
2006-10-01
影响因子：
78.5
通讯作者：
Shoemaker, Robert H.
中科院分区：
文献类型：
--
作者：
Shoemaker, Robert H.
美国国家癌症研究所（NCI）60人类肿瘤细胞系抗癌药物筛选（NCI 60）是在20世纪80年代末开发的，作为体外药物发现工具，旨在取代抗癌药物筛选中使用的可移植动物肿瘤。这种筛选模型很快被认为是关于生长抑制和肿瘤细胞杀伤机制的丰富信息来源。最近，它的角色已经改变为支持癌症研究社区的服务屏幕。在这里，我回顾了屏幕的开发，使用和生产力，突出了几个结果，有助于癌症化疗的进步。
The US National Cancer Institute (NCl) 60 human tumour cell line anticancer drug screen (NCl60) was developed in the late 1980s as an in vitro drug-discovery tool intended to supplant the use of transplantable animal tumours in anticancer drug screening. This screening model was rapidly recognized as a rich source of information about the mechanisms of growth inhibition and tumour-cell kill. Recently, its role has changed to that of a service screen supporting the cancer research community. Here I review the development, use and productivity of the screen, highlighting several outcomes that have contributed to advances in cancer chemotherapy.